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Abstract: Glucocorticoid-induced leucine zipper (GILZ) is a glucocorticoid responsive protein 
that links the nuclear factor-kappa B (NFκB) and the glucocorticoid signaling pathways. Func-
tional and binding studies suggest that the proline-rich region at the carboxy terminus of GILZ 
binds the p65 subunit of NFκB and suppresses the immunoinflammatory response. A widely-
used strategy in the discovery of peptide drugs involves exploitation of the complementary 
surfaces of naturally occurring binding partners. Previously, we observed that a synthetic peptide 
(GILZ-P) derived from the proline-rich region of GILZ bound activated p65 and ameliorated 
experimental encephalomyelitis. Here we characterize the secondary structure of GILZ-P by 
circular dichroic analysis. GILZ-P adopts an extended polyproline type II  helical conforma-
tion consistent with the structural conformation commonly observed in interfaces of transient 
intermolecular interactions. To determine the potential application of GILZ-P in humans, we 
evaluated the toxicity and efficacy of the peptide drug in mature human macrophage-like THP-1 
cells. Treatment with GILZ-P at a wide range of concentrations commonly used for peptide 
drugs was nontoxic as determined by cell viability and apoptosis assays. Functionally, GILZ-P 
suppressed proliferation and glutamate secretion by activated macrophages by inhibiting nuclear 
translocation of p65. Collectively, our data suggest that the GILZ-P has therapeutic potential 
in chronic CNS diseases where persistent inflammation leads to neurodegeneration such as 
multiple sclerosis and Alzheimer’s disease.
Keywords: glucocorticoid-induced leucine zipper, therapeutic potential, translational impact, 
chronic inflammation
Introduction
Persistent inflammation is widely recognized as a common denominator in the patho-
genesis of multiple diseases with diverse clinical manifestations, such as immune-
mediated rheumatoid arthritis or multiple sclerosis and neurodegenerative Alzheimer’s 
disease or Parkinson’s disease.1–5 Sustained or unregulated activation of the transcription 
factor nuclear factor kappa B (NFκB) is integral to the persistence of inflammation.6,7 
The most common form of NFκB is a heterodimer of p50 and p65 subunits. In resting 
cells, NFκB exists in the cytoplasm as an inactive complex bound to IκB inhibitory 
proteins.2,8 Activation of NFκB signaling induces proteolytic degradation of IκB inhibi-
tory proteins, releasing the p50 and p65 subunits. p65 is the functionally dominant 
subunit that, upon release from the inhibitory complex, translocates to the nucleus, 
where it binds cognate NFκB binding sites in the DNA and modulates  expression 
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Figure 1 The gilZ protein and peptide.
Notes: (A) Primary structure of human gilZ showing different domains. The proline-rich region with “PXXP” motifs is highlighted. homology models of (B) mouse or 
(C) human gilZ using porcine δ sleep-inducing peptide (PDB: 1DiP) as the template are shown. The proline in helical poly-l-proline type ii conformation is shown in blue. 
Models of gilZ mutants are shown with (D) alanine substitution of proline residues or (E) both proline and glutamic acid residues in the proline-rich region. The alanine 
substituting the poly-l-proline type ii helical proline is shown in blue. (F) Table showing the ψ and φ dihedral angles of potentially critical proline residues in the carboxy 
terminus of the human and mouse gilZ models and the indicated mutants.
Abbreviations: gilZ, glucocorticoid-induced leucine zipper; Tsc, TgF-beta stimulated clone-box. 
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of several genes involved in apoptosis, and immune and 
 inflammatory responses.2,7
Mechanistically, many drugs used in the treatment of 
chronic inflammatory pathologies act at least in part by 
inhibiting NFκB transactivation. For example, the effects 
of many of the nonsteroidal anti-inflammatory drugs are 
mediated by suppression of NFκB activation by inhibiting 
the IκB complex or by activation of peroxisome proliferator-
activated receptor gamma, a negative regulator of NFκB 
transcription.2,9 The profound anti-inflammatory effects of 
the widely-used glucocorticoids10 as well as the therapeutic 
efficacy of many currently approved biologics has been 
attributed to indirect inhibition of NFκB signaling.11,12 
 However, nonspecific responses, serious adverse effects, 
and/or high cost are some of the factors that compromise 
long-term use of these therapeutic agents.
Interactome analysis using MetaCore™ (Thomson 
 Reuters, New York, NY, USA) identified glucocorticoid-
induced leucine zipper (GILZ) as a  “divergence” hub 
functionally linked to multiple proteins in the NFκB and 
glucocorticoid signaling pathways.13 GILZ was identified 
originally during systematic study of genes  transcriptionally 
induced by glucocorticoids.14,15  Functionally, GILZ has 
been shown to suppress immune responses by preventing 
signaling via AKT or PKB (protein kinase B)/Ras proteins, 
inhib iting cyclooxygenase -2 (Cox-2) activity, and skewing 
proinflammatory cytokine(interferon gamma [IFN-γ], tumor 
necrosis factor alpha [TNF-α]) responses to anti-inflammatory 
cytokine (interleukin [IL]-10, transforming growth factor 
beta [TGF-β]) responses.16–19 Mechanistically, the inhibitory 
potential of GILZ is attributed to its ability to bind and prevent 
nuclear translocation of p65, thereby inhibiting transactivation 
of pathological mediators.16,20 Indeed, it is suggested that the 
profound therapeutic efficacy of glucocorticoids could be 
attributed to the induced upregulation of GILZ.21,22
Structurally, GILZ has an amino terminal-dimerizing 
leucine zipper motif and a proline-rich carboxy terminus (Fig-
ure 1A). Mutational analysis suggested that the p65 binding 
domain of GILZ is localized in the proline-rich region of its 
carboxy terminus.20,23 In the eukaryotic  proteome, proline-rich 
regions are widely represented in the interfaces of transient 
protein-protein interactions and are considered attractive 
targets for drug development.24,25 A common strategy in the 
discovery of peptide drugs involves exploitation of the comple-
mentary surfaces of the naturally occurring binding partners.26 
We observed that a synthetic peptide (GILZ-P) derived from 
the proline-rich region of GILZ suppressed immune-mediated 
inflammatory responses in mice.27 Kinetic analysis suggested 
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the strength of interaction between the GILZ and the p65 
proteins to be in micromolar concentrations consistent with 
observations in transient intermolecular interactions.27,28 In this 
study, we characterized the secondary structure of GILZ-P, 
investigated its toxicity, and evaluated its functional potential 
in human macrophage-like THP-1 cells.
Materials and methods
Peptides and preparation  
of Pep-1:peptide complexes
GILZ-P
115–137
 (Figure 1B) and control peptides (Control-P) 
of scrambled residues were synthesized as peptide amides 
with amino terminal acetylation. All peptides were 95% 
pure by mass spectrometry. Intracellular delivery of GILZ-P 
and Control-P was achieved using the Pep-1 chariot reagent 
(Active Motif, Carlsbad, CA, USA). Immediately prior to 
each experiment, a noncovalent complex of the chariot and 
peptide drug was formed by combining Pep-1 and GILZ-P 
or Control-P at appropriate concentrations in 100 µL of 
sterile phosphate-buffered saline and incubating at room 
 temperature for 30 minutes.29 The noncovalent complex of 
Pep-1 with GILZ-P and Control-P will henceforth be referred 
to as GILZ-P
c
 or Control-P
c
.
circular dichroism
Circular dichroism (CD) spectra were collected on a MOS450 
AF/CD spectrometer (Bio-Logic Science Instruments , Clarix, 
France) at 25°C in the 190–270 nm wavelength range with a 
0.5 nm resolution and a scan rate of 200 nm per minute. The 
samples were prepared by dissolving  lyophilized GILZ-P and 
Control-P at a 100 µM concentration in citrate buffer (1 mM 
sodium citrate, 1 mM sodium borate, 1 mM sodium phosphate, 
15 mM NaCl) with pH adjusted at 7.0. Each spectrum was 
measured five times with individually prepared solutions. Raw 
CD signals were converted to mean residue molar ellipticity (θ)
MRW
 in degrees cm2/dmol using the formula [θ]
MRW
 = [θ]
obs
/10 l 
c n, where [θ]
obs
 represents the observed ellipticity, l is the path 
length in centimeters, c is the molar concentration of peptide, 
and n is the number of residues in the peptide. To determine 
0% polyproline type II (PPII) helical content, CD spectra were 
recorded with GILZ-P and Control-P dissolved in 6 M CaCl
2
.28 
The data used for graphical presentation and analyses were 
each an average of five different scans.
cell cultures
The human monocytic cell line, THP-1 (a gift from Dr Michael 
Klemsz, Department of Immunology, Indiana University 
School of Medicine, Minneapolis, IN, USA) was maintained 
in complete Roswell Park Memorial Institute (RPMI)-1640 
medium (Sigma-Aldrich, St Louis, MO, USA) supplemented 
with 1% L-glutamine, 5 mM β-mercaptoethanol, and 10 mM 
N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
(HEPES) (Life Technologies, Carlsbad, CA, USA), with 10% 
heat-inactivated fetal calf serum, 100 U/mL penicillin, and 
100 µg/mL streptomycin, and seeded in 75 cm2 flasks at a 
density of 5×106 cells per flask. The cells were cultured in 
5% CO
2
 atmosphere at 37°C , and the medium was changed 
every 2–3 days.30 For differentiation to mature macrophages, 
cultured THP-1 cells were initially rested for 24 hours in 
fresh medium without antibiotics. Next, the cells were seeded 
at 5×105 cells/mL in a new 75 cm2 flask and stimulated with 
200 nM of phorbol-12 myristate 13-acetate (PMA; Sigma-
Aldrich) for 72 hours.31 Previously, PMA has been shown 
to induce THP-1 cells to differentiate into mature human 
macrophages.31–33 The differentiation was confirmed by flow 
cytometric analysis for expression of the macrophage-specific 
markers, CD14 and CD11c. The cells were then washed 
to remove PMA and rested in fresh complete RPMI-1640 
medium for 24 hours prior to use in experiments.31,32
cell viability and apoptosis assays
THP-1 cells (1×106/mL) suspended in complete RPMI-
1640 were incubated in the presence of medium-alone or 
increasing concentrations of GILZ-P
c
 (10–640 µM) in a 5% 
CO
2
 incubator at 37°C. The viability of cells harvested at 1, 
4, 8, 12, 24, and 48 hours was determined by trypan blue 
exclusion using a Countess automated cell counter (Thermo 
Fisher Scientific, Waltham, MA, USA).34 Adherent cells were 
treated with 0.5 mL of 0.05% trypsin-0.5 mM ethylenedi-
aminetetraacetic acid (EDTA) (Thermo Fisher Scientific) 
at 37°C for approximately 5 minutes to enhance removal. 
In separate experiments, THP-1 macrophages cultured 
similarly were harvested at different time points and stained 
with Annexin V and propidium iodide using the Annexin-V-
FLUOS staining kit (Roche Diagnostics, Indianapolis, IN, 
USA) according to the manufacturer’s protocol. Incubation 
of cells with actinomycin D was used as a positive control 
for apoptosis.  Fluorescence was detected by flow cytometry 
(FACS  Calibur™; BD Biosciences, Palo Alto, CA, USA). 
Fluorescence parameters were gated using unstained cells. 
Data shown are expressed as percentages of Annexin 
V- positive cells for quantitation of apoptosis.31,32
internalization assays
THP-1 cells (1×106/well) in serum-free RPMI-1640 were 
exposed to the Pep-1:GILZ-P complex at increasing molar 
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ratios of 0.1 to 50 and incubated at 37°C in a humidified 5% 
CO
2
 chamber. Cells harvested at 15 minutes, 30 minutes, 
1 hour, and 4 hours were lysed, and the cytoplasmic fraction 
was isolated using the nuclear cytoplasmic extraction kit fol-
lowing the manufacturer’s protocol (Pierce Biotechnology, 
Rockford, IL, USA). An equal quantity of the cytoplasmic 
fraction (20 µL) in 100 µL of phosphate-buffered saline 
(PBS) was plated in 96-well high affinity enzyme-linked 
immunosorbent assay (ELISA) plates and probed for the 
presence of GILZ-P with 20 µM recombinant human p65 
protein (rp65-DDK;  OriGene Technologies, Inc., Rockville, 
MD, USA).  Previously we observed that GILZ-P at 15 µM 
binds purified p65  protein with a dissociation constant of 
1.12±0.25 × 10−6 M.27 Wells coated with  Pep-1:GILZ-P 
at a specific molar ratio (0.1 to 50) constituted positive 
controls. The GILZ-P-bound p65 detected with anti-DDK 
monoclonal antibody was visualized by trinitrobenzene 
substrate and 2 N sulfuric acid. Absorbance at 450 nM 
was measured using an absorbance microplate reader 
(Model 680; Bio-Rad Laboratories,  Hercules, CA, USA). 
 Presence of GILZ-P was determined using the  equation: 
% GILZ-P = (OD
treated
 − OD
cells only
/OD
pos
)*100 (where OD 
represents optical density).
In separate experiments, THP-1 cells (1×106/well) cultured 
similarly in the presence of Pep-1:GILZ-P complex as above 
or with Pep-1:recombinant GILZ (rGILZ) (Abnova,Taipei 
City, Taiwan) at 20:1 molar ratio were permeabilized at the 
end of 24 hours. The presence of intracellular GILZ-P was 
determined by sequentially incubating the permeabilized cells 
with 20 µM rp65-DDK followed by phycoerythrin-conjugated 
anti-DDK monoclonal antibody at 4°C for 30 minutes. After 
washing briefly, the cells were fixed in 2% paraformalde-
hyde and analyzed immediately using a FACSCalibur flow 
cytometer. Mean fluorescence intensity was representative 
of the amount of GILZ-P-bound p65. Data are presented as 
the average of two independent experiments.
cell proliferation
THP-1 macrophages (1×106/mL) were preincubated inde-
pendently with 100 µL of 80 μM GILZ-P
c
/Control-P
c
/ 
GILZ-P/Control-P/(2 µL) Pep-1 alone at 37°C in humidi-
fied 5% CO
2
 for 30 minutes. The cells were then suspended 
in complete RPMI-1640 medium, seeded in 24-well plates 
in a total volume of 1 mL/well and cultured in the pres-
ence or absence of lipopolysaccharide (LPS) 2 µg/mL.35 
In some wells, the lipopolysaccharide-stimulated cells 
were treated with dexamethasone 0.3 mg/mL. At the end 
of 72 hours, 25 µL of MTT (3-[4,5-Dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) solution at 5.0 mg/mL 
was added to each well and incubated at 37°C for 3 hours. 
The plates were then centrifuged at 1,000 rpm in a clinical 
centrifuge for 5 minutes. The supernatants were removed 
and 150 µL of the MTT solvent (10% isopropanol and 
50% sodium dodecyl sulfate) was added to each well and 
the plates were incubated at 37°C with mild shaking for 
30 minutes. Optical density measurements were recorded 
at 540 nM absorbance using a Gensys 5 spectrophotometer 
(Thermo Fisher Scientific). The viability of THP-1 cells 
was indicated by the absorbance at 540 nM of the reduced 
formazan formed in living cells. The absorbance in all test 
samples was normalized to the cells cultured with medium-
alone. All experiments were performed in triplicate and the 
data are presented as the mean ± standard deviation.
In independent experiments, THP-1 macrophages treated 
as above with 80 µM GILZ-P
c
/Control-P
c
/(2 µL) Pep-1 alone 
or dexamethasone were stimulated similarly with lipopoly-
saccharide 2 µg/mL or medium-alone. The supernatant was 
collected at the end of 24, 48, and 72 hours, and was stored 
at −80°C until further analysis.
elisa for cytokines
Cytokines in the culture supernatant were measured 
by ELISA using Opt EIA kits for IFN-γ, IL-12, IL-6 
(BD  Biosciences) or Quantikine ELISA kits for TNF-α (R&D 
Systems,  Minneapolis, IN, USA).36 Briefly, 96-well enzyme 
 immunoassay plates (Thermo Fisher Scientific) coated with 
the appropriate concentration of the primary antibody were 
applied 50 µL of culture supernatant in triplicates. The pres-
ence of cytokine was probed using the appropriate detection 
antibody and detected using the streptavidin enzyme conju-
gate followed by color development. The optical density of 
each well was determined using a microplate reader set to 
450 nm. The concentration of cytokines was calculated in 
comparison with the standard series diluted in two-fold steps. 
Limits of detection were 31.2, 3.9, 3.9, and 7.8 pg/mL for 
IL-12, IFN-γ, IL-6, and TNF-α, respectively.
nFκB assay
THP-1 macrophages (1×106/mL) were preincubated with 
100 µL of 80 µM GILZ-P
c
/Control-P
c
/(2 µL) Pep-1 alone at 
37°C in humidified 5% CO
2
 for 30 minutes. The cells were 
then suspended in serum-free RPMI-1640 medium, seeded 
in 24-well plates, and cultured in the presence or absence 
of LPS 2 µg/mL. In some wells, the LPS-stimulated cells 
were treated with dexamethasone 0.3 mg/mL. Nuclear 
extracts were prepared from cells harvested after 4 hours 
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of culture using the nuclear extraction kit following the 
recommended protocol (Active Motif). Activated NFκB 
in each sample was determined by oligonucleotide-based 
ELISA using the TransAM kit protocol (Active Motif). Five 
micrograms of nuclear extract was incubated in a 96-well 
plate coated with oligonucleotides containing the NFκB 
consensus nucleotide sequence (5′-GGGACTTTCC-3′). 
The activated NFκB bound to DNA was detected by the 
anti-p65 antibody followed by the horseradish peroxidase-
conjugated secondary antibody and visualized using 
hydrogen peroxide/TMB (3,3′ 5,5′-tetramethylbenzidine) 
chromogenic substrate. The p65 binding was calculated 
as the ratio of absorbance of the LPS-stimulated cells to 
unstimulated cells for each test sample. Nuclear extracts of 
Raji cells provided in the kit were used as the positive con-
trol for nuclear p65. In separate experiments, to determine 
the dose response, the THP-1 macrophages preincubated 
with GILZ-P
c
 or Control-P
c
 at varying concentrations 
(10, 40, and 80 µM) were cultured similarly. The nuclear 
extracts harvested from cells at 4 hours were assessed for 
activated p65 as mentioned.
glutamate production
THP-1 macrophages (0.5 × 106/well) pretreated with 80 µM 
GILZ-P
c
/Control-P
c
/(2 µL) Pep-1 alone were cultured in 
complete RPMI-1640 medium in the presence or absence of 
LPS 2 µg/mL as above. In some wells, the LPS-stimulated 
cells were treated with dexamethasone 0.3 mg/mL. The 
concentration of glutamate in the culture supernatant col-
lected at the end of 24 hours was measured using a com-
mercially available glutamate colorimetric assay following 
the manufacturer’s protocol (BioVision Inc., Milpitas, CA, 
USA).31,37 Briefly, glutamate standard (0, 2, 4, 6, 8, 10 nmol/
well) and culture supernatant diluted 1:4 in the assay buffer 
provided in the kit was added to 96-well plates in triplicate. 
To each well was added a reaction mixture containing 0.8% 
glutamate developer and 0.2% glutamate enzyme mix in the 
assay buffer. The glutamate enzyme mix recognizes glutamate 
as a specific substrate leading to proportional yellow color 
development, and the amount of glutamate is measured by 
reading the absorbance at 450 nM in a microplate reader. Wells 
added assay buffer and developer in the absence of glutamate 
enzyme served as background controls. The net absorbance 
in supernatants of each sample calculated by subtracting the 
values of the background wells was used to determine the 
amount of glutamate using the standard curve. The  glutamate 
concentration in each sample was calculated using the formula 
C = Sa/Sv nmol/µL, where Sa is the sample amount of known 
(in nmol) from the standard curve and Sv is the sample vol-
ume (µL) added into the wells. The low limit of detection 
was 2 nmol/µL. The experiment was repeated twice and the 
data presented represent the average of two  experiments. To 
determine the dose response, in separate experiments the 
THP-1 macrophages preincubated with GILZ-P
c
 or Control-P
c
 
at varying concentrations (10, 40, and 80 µM) were cultured 
similarly and supernatants collected at 24 hours were mea-
sured for glutamate secretion as mentioned.
statistical analysis
Differences in the proliferation, cytokine secretion, gluta-
mate production, and p65 activity between the untreated and 
treated (with GILZ-P
c
/Control-P
c
/dexamethasone/GILZ-P, 
Control-P/Pep-1 alone) macrophages were determined by 
pairwise comparison using the Student’s t-test. A difference 
at P0.05 was considered to be statistically significant.
Results and discussion
rationale and design of gilZ-P
The carboxy terminus of GILZ (GILZ-COOH) spans 
40 residues (98–137), with eight glutamic acid residues, 
eight prolines, and five “PXXP” motifs14,21 (Figure 1A). The 
primary sequence of GILZ is highly homologous to that 
of porcine δ sleeping-inducing peptide (DSIP). In models 
of GILZ generated using the solution structure of DSIP 
(PDB:1 DIP) as a template, secondary structure assign-
ment by PROSS showed that the Pro123 of human GILZ 
exhibits ϕ and φ angles of −64.5° and 149.8°, respectively, 
adopting a helical poly-l-proline type II (PPII) conforma-
tion27,38,39 (Figure 1B). The presence of multiple glutamic 
acid residues in the region increases the net charge, further 
promoting the extended PPII conformation by electro-
static repulsion.40 Replacement of both glutamic acid and 
the proline residues in the proline-rich region by alanine 
abrogated the ability of GILZ to inhibit NFκB, potentially 
due to an induced bend that disrupts the extended PPII 
conformation21,22 (Figure 1C). Binding studies suggested 
that the GILZ protein interacts with the transactivation 
domain at the carboxy terminus of p65.27 Similar to the 
frequently observed features in structural complexes with 
fast binding kinetics, the C-H-π interaction between the 
imino ring of the critical prolines of GILZ and the aromatic 
ring of the conserved F534 and F542 in the p65 transac-
tivation domain could contribute to the binding energy 
of the GILZ:p65 complex.41–43 The planar structure of the 
aromatic side chains are complementary to the ridges and 
grooves presented on the PPII helix.41,43 Taken together, 
Drug Design, Development and Therapy 2014:8
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these observations implicate a short proline-rich motif 
at the GILZ-COOH as critical for interacting with and 
inhibiting p65 transactivation.
Considerable success has been achieved in adopting the 
results from mutagenesis and structural studies to design 
small molecule antagonists of protein-protein interactions.44,45 
This approach relies on the premise that the key residues of 
the binding epitope, in particular the side chain functional 
groups responsible for the binding affinity between two 
proteins may be transferred to a much smaller molecule with 
contributions to the binding largely intact.44,46 The approach 
is particularly effective for proline-rich motifs that prefer-
entially adopt a helical PPII conformation, since absence 
of the backbone hydrogen donor on proline allows the free 
carbonyls to participate in intermolecular hydrogen bonds. 
In contrast with the enthalpy-induced associations, such as 
the lock and key model, PPII helices are entropy-driven and 
behave as “adaptable gloves” in order to obtain the correct 
recognition.47 Further, the side chain and the backbone car-
bonyls that point outwards at regular intervals can be easily 
“read” by the interacting protein, making the PPII helix an 
excellent recognition motif40 and potential therapeutic lead. 
We hypothesized that a peptide derived from the proline-rich 
carboxy terminus of GILZ (ie, GILZ-P) would adopt a helical 
PPII conformation and inhibit p65 transactivation.47 To mimic 
the end groups of the p65 binding domain of GILZ and to 
stabilize the secondary structure, GILZ-P was synthesized as 
an amide with acetylation of the amino terminus.28
gilZ-P adopts a helical  
PPii conformation
The best way to unambiguously reveal the PPII struc-
ture in solution is to use spectroscopies based on optical 
activity, such as CD. As seen in Figure 2A, the CD 
spectrum of GILZ-P presented a strong negative band 
(θ = −20.03×103 deg ⋅ cm2/dmol) at 199 nm and a weak  positive 
band (θ = 1.12×103 deg cm2/dmol) at 238 nm, consistent 
with the spectrum of polypeptides that prefer a helical PPII 
structure.8,15 An increase in temperature to 90°C or spectral 
analysis of GILZ-P in 5 M CaCl
2
 resulted in a dramatic decrease 
in the intensity of the mean residue ellipticity minimum 
(θ = −8.84×103deg ⋅ cm2/dmol at 205 nM and θ = −11.37× 
03deg ⋅ cm2/dmol at 204 nM, respectively) due to transition 
from the PPII helix to random coil conformation13 (Figure 2A). 
The CD spectrum of Control-P1 and Control-P2 at 194 nm 
showed a weak minimum of θ = 4.5 × 101 deg ⋅ cm2/dmol and 
θ = −3.5×101 deg ⋅ cm2/dmol, respectively (Figure 2B). 
Control-P1 was used in further cellular experiments.
effects of gilZ-P on cell viability  
and apoptosis
GILZ-P is developed as a potential NFκB inhibitory agent. 
As a first step to investigate the possibility of using GILZ-P 
in humans, we assessed the effect of GILZ-P on the viabil-
ity of human macrophage-like THP-1 cells by trypan blue 
exclusion using an automated cell counter.34 THP-1 cells 
were treated with increasing concentrations of GILZ-P
c
 
(10–640 µM). The range of concentration is equivalent to 
0.028–1.8 mg/mL and represents the dose range  commonly 
used for peptide therapeutics.48–50 The viability of cells was 
assessed at 1, 4, 8, 12, 24, and 48 hours following exposure to 
GILZ-P
c
. Cells cultured in medium-alone maintained viabil-
ity of 70%–100% at all time points (Figure 3A). Although the 
viability of THP-1 cells decreased with increasing concentra-
tions of GILZ-P
c
, more than 40% of cells remained viable, 
even in cultures treated with the  highest  concentration of 
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GILZ-P
c
 at 640 µM (Figure 3B). The mean percent viability 
of cells exposed to 640 µM GILZ-P
c
 at 1 hour and 48 hours 
was 72%±4.5% and 45%±5.5%, respectively.
We next investigated the cellular toxicity of GILZ-P 
by staining for the apoptosis-specific and necrosis-specific 
markers, Annexin V and propidium iodide, respectively. 
Flow cytometric analysis showed that the mean percent 
apoptosis of THP-1 cells cultured in medium-alone and 
harvested at 4, 8, and 24 hours was 0.32±0.7, 0.53±0.7, and 
1.003±0.22, respectively (data not shown). Representative 
histograms of percent apoptosis in THP-1 cultures exposed 
to 0, 40, or 80 µM of GILZ-P
c
 at 4, 8, and 24 hours are 
shown in Figure 3D–F. A dramatic increase was observed 
in the mean percent apoptosis of THP-1 cells treated with 
80 µM (3.48±0.4%) GILZ-P
c
 as compared with cells 
exposed to 40 µM GILZ-P
c
 (1.03±0.24%) at the 4-hour time 
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Figure 3 effect of gilZ-P on viability of ThP-1 monocytes.
Notes: ThP-1 cells were incubated with increasing concentrations of gilZ-Pc from 10 µM to 640 µM at 37°c for increasing time periods from 1 hour to 48 hours. The 
control consisted of cells incubated in medium-alone. at indicated time points, the percentage of live cells was determined by trypan blue exclusion. (A) shows percentage 
viability in control cells cultured in medium at indicated time points. (B) represents the percentage of live cells treated with the indicated concentration of gilZ-Pc at 
specified times. Data are normalized with respect to the cells cultured in medium-alone at each time point and represent the mean ± standard deviation of three independent 
experiments. (C) gilZ-P-treated macrophages stimulated with lPs and treated similarly were stained with annexin V (apoptosis marker) and propidium iodide (necrosis 
marker) and subjected to fluorescence-activated cell sorting analysis to determine apoptosis. The mean percentage of Annexin V-positive THP-1 cells treated with GILZ-Pc 
at indicated concentrations and analyzed at indicated time points is shown. Data represent the mean ± standard deviation of three independent experiments. representative 
histogram of the percentage of apoptosis in ThP-1 cultures exposed to (D) 0, (E) 40 µM, or (F) 80 µM of gilZ-Pc at indicated time point is shown. (G) representative 
histogram of dual positive (annexin V and propidium iodide) ThP-1 cells treated with actinomycin D as the positive control.
Abbreviations: gilZ, glucocorticoid-induced leucine zipper; gilZ-P, synthetic peptide derived from the proline-rich region of gilZ; gilZ-Pc, noncovalent complex of 
Pep-1 with gilZ-P; lPs, lipopolysaccharide; h, hours.
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point ( Figure 3C). The mean percent apoptosis of THP-1 
cells exposed to GILZ-P
c
 at the highest concentration of 
640 µM at 4, 8, and 24 hours was 7.62±0.3%, 9.06±1.9% 
and 12.88±2.9%, respectively (Figure 3C). The mean percent 
dual positive THP-1 cells (apoptotic and necrotic) exposed to 
80 µM or 640 µM of GILZ-P
c
 at 24 hours was 28.9±1.01% 
and 60.3±3.2%, respectively. The mean percent dual posi-
tive THP-1 cells treated with actinomycin D and harvested 
at 4, 8, and 24 hours was 26.9±7.5%, 59.1±9.2%, and 
98.4±2.1%, respectively. A representative histogram of dual 
positive THP-1 cells treated with actinomycin D is shown 
in  Figure 3G. Collectively, these observations suggest that 
GILZ-P is largely nontoxic.
gilZ-P prevents lPs-induced 
proliferation and cytokine secretion
GILZ-P acts by binding p65 in the cytoplasm and should be 
delivered into the cell to be effective as a therapeutic agent.28 
Cytoplasmic fractions of THP-1 cells exposed to increasing 
concentrations of Pep-1:GILZ-P complex were assessed for 
binding purified p65 as a measure of intracellular presence 
of GILZ-P by modified ELISA. The highest intracellular 
presence of GILZ-P was observed in cells exposed to a 
10:1 molar ratio of Pep-1:GILZ-P (Figure 4A). In addition, 
a dose response of intracellular concentration of GILZ-P 
was observed during early time points. In separate experi-
ments, THP-1 cells exposed to increasing molar ratios of 
Pep:1-GILZ-P complex were permeabilized at the end of 
24 hours. The permeabilized cells were probed with 
rp65-DDK as an indirect measure of intracellular GILZ-P. 
Flow cytometric analysis of permeabilized THP-1 cells 
showed that the maximum internalization of the peptide was 
observed in cells exposed to GILZ-P:Pep-1 at a 1:10 molar 
ratio (Figure 4B). Interestingly, with increasing concentra-
tions of Pep-1, the internalization efficiency was reduced 
(Figure 4A and B). Similar observations for cargo delivery 
by Pep-1 have been reported previously.51
To determine the inhibitory potential, we next assessed 
the functional efficacy of GILZ-P
c
 in PMA-differentiated 
THP-1 macrophages. The membrane integrity and prolifera-
tion of THP-1 macrophages stimulated with LPS and treated 
with dexamethasone/80 µM GILZ-P
c
/Control-P
c
, GILZ-P/
Control-P/(0.2 µL) Pep-1 alone for 72 hours was determined 
by MTT colorimetric assay. The viability of THP-1 cells 
(as indicated by absorbance at 540 nM) was significantly 
higher in cultures treated with dexamethasone (228.5±23.6)/
GILZ-P
c
 (251±14.5) than in untreated cultures (168.3±19.6) 
or Control-P
c
-treated cultures (175.6±9.1,  Figure 5A). No 
significant difference was observed in viability of cells 
stimulated in the presence of GILZ-P (165.8±10)/Control-
P (149.6±13.8)/Pep-1 alone (133.3±0.3) as compared with 
untreated cells (168.3±19.6, Figure 5A).
We then investigated whether the reduced prolifera-
tive index mediated by GILZ-P
c
 was reflected by cytokine 
 secretion in LPS-stimulated THP-1 macrophages. Mea-
surement of cytokines by ELISA suggested that at the 
end of 24 hours, macrophages stimulated with LPS and 
treated with GILZ-P
c
 80 µM or dexamethasone 0.3 mg/mL 
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Figure 5 effect of gilZ-P on proliferation and cytokine responses.
Notes: ThP-1 cells (1×106/ml) in 100 µl of serum-free rPMi-1640 medium were preincubated in 100 µl of 80 µM gilZ-Pc, control-Pc, gilZ-P, control-P, or (2 µl) Pep-1 
at 37°C in humidified 5% cO2 for 30 minutes. in some cultures, ThP-1 cells were treated with dexamethasone 0.3 mg/ml. The cells were then suspended in complete rPMi-
1640 medium and cultured in the presence or absence of lPs 2 µg/ml for 72 hours. cell viability was determined by the colorimetric MTT assay (A). Values are normalized 
for the cells cultured in medium-alone. The data represent the mean ± standard deviation of three independent experiments. *P0.05. in separate experiments, supernatants 
collected at 24 hours from THP-1 macrophages cultured similarly were assessed for specific cytokines (B, D, F and H) by elisa. To determine kinetics, the supernatant 
from separate ThP-1 cultured cells was similarly harvested at the end of 24, 48, and 72 hours and the indicated cytokines were measured. (C, E, G and I). The cytokine 
concentrations in the samples were calculated in comparison with standard series (insets). The data represent the mean of three independent experiments. *P0.05.
Abbreviations: elisa, enzyme-linked immunosorbent assay; gilZ, glucocorticoid-induced leucine zipper; gilZ-P, synthetic peptide derived from the proline-rich region 
of gilZ; lPs, lipopolysaccharide; gilZ-Pc, noncovalent complex of Pep-1 with gilZ-P; MTT, 3-(4,5-dimethyl-thiazol-2-yl)-2,5 diphenyl tetrazolium bromide; TnF-a, tumor 
necrosis factor-a; iFn-γ, interferon gamma; Dex, dexamethasone; rPMi, roswell Park Memorial institute. 
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Figure 6 effect of gilZ-P on nFκB activation in macrophages.
Notes: (A) ThP-1 macrophages (1 × 106/ml) were preincubated with 80 µM gilZ-Pc, control-Pc, or (2 µl) Pep-1 alone at 37°C in humidified 5% cO2 for 30 minutes. 
The cells were then cultured in serum-free medium in the presence or absence of lPs (2 µg/ml). some cells were stimulated in the presence of dexamethasone 0.3 mg/ml. 
nuclear extracts obtained from cells harvested at the end of 4 hours were tested for binding of the activated p65 nFκB subunit to an nFκB consensus sequence using the 
TransaM nFκB elisa kit. (A) p65 Dna binding activity was calculated as the ratio of absorbance from lPs-stimulated cells to that of unstimulated cells. (B) To determine 
the dose effect, ThP-1 cells preincubated with increasing concentrations (10, 40, and 80 µM) of gilZ-Pc or control-Pc were cultured similarly in separate experiments and 
the nuclear extracts assessed for activated p65. The mean absorbance of cells cultured in medium-alone at 450 nM varied between 0.112 and 0.245. Values are the mean ± 
standard deviation of three experiments performed in duplicate. *P0.05.
Abbreviations: elisa, enzyme-linked immunosorbent assay; gilZ, glucocorticoid-induced leucine zipper; gilZ-P, synthetic peptide derived from the proline-rich region of 
gilZ; gilZ-Pc, noncovalent complex of Pep-1 with gilZ-P; lPs, lipopolysaccharide; Dex, dexamethasone.
secreted significantly less TNF-α, IL-12, IFN-γ, and IL-6 
as compared with the untreated or Control-P
c
-treated 
cells (Figure 5B, D, F, and H). Time course  analysis sug-
gested that the reduction in TNF-α and IL-6 was more 
pronounced at 24 hours (Figure 5C and I) and that IFN-γ 
 production was most significant in 72-hour cultures of 
GILZ-P
c
-treated THP-1 macrophages (Figure 5E). The 
concentration of IL-12 was significantly lower in LPS-
stimulated GILZ-P
c
-treated cells at all time points measured 
as compared with the untreated THP-1 cells (Figure 5G). 
Taken together, these observations suggest that GILZ-P at 
a concentration of 80 µM inhibits proliferation and proin-
flammatory cytokine secretion by LPS-stimulated mature 
macrophages.
gilZ-P treatment inhibits activated p65
LPS stimulation has previously been shown to enhance 
expression of activated NFκB in naïve THP-1 cells as well 
as in PMA-differentiated THP-1 macrophages.33 We mea-
sured nuclear p65 using activated NFκB-specific ELISA and 
report the p65 binding  activity as the ratio of absorbance in 
nuclear extracts from LPS-stimulated THP-1 macrophages 
to that in unstimulated cells. LPS- stimulated THP-1 mac-
rophages treated with dexamethasone/GILZ-P
c
 exhibited 
reduced nuclear p65 as compared with untreated cells 
(Figure 6A). A dose-dependent reducing trend of nuclear 
p65 was observed in LPS-stimulated GILZ-P
c
-treated THP-1 
macrophages  (Figure 6B).  Treatment with Control-P
c
, 
GILZ-P, or Pep-1 alone was not associated with a significant 
difference in nuclear p65 as compared with the untreated 
cells (Figure 6A and B). Collectively, these observations 
suggest that, much like glucocorticoids and other synthetic 
agents, such as aspirin and nanocurcumin,52–56 GILZ-P 
treatment also  potentially suppresses cytokine responses by 
inhibiting NFκB activity.
gilZ-P suppresses glutamate release  
by lPs-stimulated mature ThP-1 cells
In addition to the measurement of the cytokines and NFκB 
activation, assessment of other biologically active molecules 
integrally involved in the pathological process, such as glu-
tamate in neuroinflammatory diseases, is often assessed as 
outcomes in early stages of drug discovery.30,57 We investi-
gated whether treatment with GILZ-P could modulate glu-
tamate secretion in LPS-stimulated THP-1 cells secondary 
to the observed NFκB blockade. A measurable amount of 
 glutamate (395.5±22.4 µM) was detected in the supernatant 
of unstimulated THP-1 cells (Figure 7A). LPS stimulation 
upregulated release of glutamate by THP-1 macrophages 
(886.6±20.9 µM) and treatment with GILZ-P
c
 (595±22 µM) 
or dexamethasone (416.37±21.7 µM) significantly sup-
pressed glutamate production (Figure 7A). The reduction 
in glutamate release was observed at all concentrations of 
GILZ-P
c
 assessed (Figure 7B). No difference was observed 
in glutamate production in THP-1 cultures stimulated in 
the presence of Control-P
c
 (792.3±42.6 µM) or Pep-1 alone 
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(700.16±7.2 µM) as compared with that in untreated cells 
(605.1±20.2 µM, Figure 7B). Thus, much like prednisolone,30 
GILZ-P also inhibits glutamate secretion via activated mac-
rophages, suggesting a potential neuroprotective effect for 
the latter.
Conclusion and future directions
Proline-rich motifs participating in intermolecular interac-
tions constitute excellent drug targets for development of 
competitive inhibitors. For example, a peptide derived from 
the proline-rich region of the Wiskott-Aldrich syndrome 
protein (WASP)-interacting protein ameliorated the defects 
in reorganization of the actin cytoskeleton.26 Previously, we 
have shown that peptide mimics of the polyproline epitope 
of the CD28 receptor suppressed the immune response by 
 interfering with CD28: ligand interactions.28,58 Here we 
demonstrate that a peptide derived from the p65 binding 
proline-rich motif of the GILZ protein adopts a helical 
PPII conformation, effectively suppresses NFκB activa-
tion, and suppresses neurotoxic glutamate in differentiated 
human macrophage-like cells used as a model for micro-
glial cells. Intraperitoneal administration of GILZ-P at 
500 µg ameliorated disease in a mouse model of multiple 
sclerosis.27 Further, treatment with GILZ-P was not associ-
ated with signs of osteoporosis in mice, indicating that the 
peptide agent potentially bypasses the adverse effects of 
 glucocorticoids.59 Collectively, these observations strongly 
support the therapeutic potential of GILZ-P in chronic 
inflammatory conditions, including neuroinflammatory 
 pathologies transitioning to neurodegenerative diseases.60 
Further structural and biophysical characterization of the 
GILZ:p65 interaction will assist in the design of functionally 
efficient small-molecule GILZ-P analogs.
Acknowledgments
We sincerely appreciate the grant supports from the 
Indiana CTSI to MS and DKL.  This work was also partly 
supported by grants from National Institutes of Health 
(NIA-R01 and -R21) and Alzheimer’s Association (IIRG) 
to DKL. We sincerely appreciate assistance from Mr. Nipun 
Chopra in some of the procedures.
Disclosure
DKL: Scientific advisory board – QR Pharma, Yuma Thera-
peutics, Entia Biosciences; International advisory board – 
Drug Discovery and Therapy World Congress; stock options, 
QR Pharma; patent involving AIT-082, memantine and 
pending on acamprosate; Editor in Chief, Current Alzheimer 
Research; research grant support from Baxter Healthcare. 
MS: cofounder, Provaidya LLC., Indianapolis. CB reports 
no conflicts of interest in this work.
These disclosures and the funding sources noted in the 
Acknowledgment section had no role in study design, in the 
collection, analysis, and interpretation of data, in the writ-
ing of the report, or in the decision to submit the article for 
publication.
References
 1. Bacher S, Schmitz ML. The NF-kappaB pathway as a potential tar-
get for autoimmune disease therapy. Curr Pharm Des. 2004;10(23): 
2827–2837.
1,000
800
600
400
200
0
G
lu
ta
m
at
e 
(µ
M
)
LP
S
D
ex
LPS
Pe
p-
1
1,000
800
600
400
200
0
0
0
1
0.5
84
R2=0.9361
Glutamate (nMol)
12
G
lu
ta
m
at
e 
(µ
M
)
A B
10 µM 40 µM 80 µM
Cells only
Cells + LPS
Cells + LPS + GILZ-P
c
Cells + LPS + control-P
c
Cells + LPS + Pep-1
Ce
lls
o
n
ly
G
IL
Z-
P
(80
 µM
)
GILZ-P concentration
Co
nt
or
l
P c
Figure 7 effects of gilZ-P on glutamate concentration in cultures of human macrophages.
Notes: ThP-1 macrophages (1×106/ml) were preincubated with 80 µM gilZ-Pc, control-Pc, or (2 µl) Pep-1 alone at 37°C in humidified 5% cO2 for 30 minutes. The cells 
were then cultured in complete rPMi-1640 medium in the presence or absence of lPs (2 µg/ml) for 24 hours. in some wells, the lPs-stimulated cells were treated with 
dexamethasone 0.3 mg/ml. (A) Glutamate concentrations in the supernatants measured using a specific colorimetric assay. Concentrations of glutamate in the samples 
were calculated in comparison with standard series (inset). (B) To determine the dose effect, ThP-1 cells preincubated with increasing concentrations (10, 40, and 80 µM) 
of gilZ-Pc or control-Pc were cultured similarly in separate experiments and the supernatants were assessed for glutamate release. samples were analyzed in triplicate and 
the data represent the mean of three independent experiments. *P0.05 as compared with cells stimulated with lPs.
Abbreviations: gilZ, glucocorticoid-induced leucine zipper; gilZ-P, synthetic peptide derived from the proline-rich region of gilZ; gilZ-Pc, noncovalent complex of 
Pep-1 with gilZ-P; lPs, lipopolysaccharide; Dex, dexamethasone; rPMi, roswell Park Memorial institute.
Drug Design, Development and Therapy 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2420
srinivasan et al
 2. Grilli M, Memo M. Nuclear factor-kappaB/Rel proteins: a point of 
convergence of signalling pathways relevant in neuronal function and 
dysfunction. Biochem Pharmacol. 1999;57(1):1–7.
 3. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic 
target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage. 
2006;14(9):839–848.
 4. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the 
NF-kappaB pathway in the treatment of inflammation and cancer. 
J Clin Invest. 2001;107(2):135–142.
 5. Yan J, Greer JM. NF-kappa B, a potential therapeutic target for the 
treatment of multiple sclerosis. CNS Neurol Disord Drug Targets. 
2008;7(6):536–557.
 6. Brown GC, Neher JJ. Inflammatory neurodegeneration and mecha-
nisms of microglial killing of neurons. Mol Neurobiol. 2010;41(2–3): 
242–247.
 7. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. 
J Clin Invest. 2001;107(1):7–11.
 8. Pande V, Ramos MJ. NF-kappaB in human disease: current inhibitors 
and prospects for de novo structure based design of inhibitors. Curr 
Med Chem. 2005;12(3):357–374.
 9. Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal 
anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life 
Sci. 2007;64(11):1403–1418.
 10. Rao NA, McCalman MT, Moulos P, et al. Coactivation of GR and NFKB 
alters the repertoire of their binding sites and target genes. Genome Res. 
2011;21(9):1404–1416.
 11. Potter C, Cordell HJ, Barton A, et al. Association between anti-tumour 
necrosis factor treatment response and genetic variants within the TLR 
and NF{kappa}B signalling pathways. Ann Rheum Dis. 2010;69(7): 
1315–1320.
 12. Fraser JH, Rincon M, McCoy KD, Le Gros G. CTLA4 ligation 
attenuates AP-1, NFAT and NF-kappaB activity in activated T cells. 
Eur J Immunol. 1999;29(3):838–844.
 13. Fan H, Morand EF. Targeting the side effects of steroid therapy in 
autoimmune diseases: the role of GILZ. Discov Med. 2012;13(69): 
123–133.
 14. Cannarile L, Zollo O, D’Adamio F, et al. Cloning, chromosomal 
assignment and tissue distribution of human GILZ, a glucocor-
ticoid hormone-induced gene. Cell Death Differ. 2001;8(2): 
201–203.
 15. D’Adamio F, Zollo O, Moraca R, et al. A new dexamethasone-induced 
gene of the leucine zipper family protects T lymphocytes from TCR/
CD3-activated cell death. Immunity. 1997;7(6):803–812.
 16. Ayroldi E, Zollo O, Bastianelli A, et al. GILZ mediates the antiprolifera-
tive activity of glucocorticoids by negative regulation of Ras signaling. 
J Clin Invest. 2007;117(6):1605–1615.
 17. Berrebi D, Bruscoli S, Cohen N, et al. Synthesis of glucocorticoid-
induced leucine zipper (GILZ) by macrophages: an anti-inflammatory 
and immunosuppressive mechanism shared by glucocorticoids and 
IL-10. Blood. 2003;101(2):729–738.
 18. Cannarile L, Cuzzocrea S, Santucci L, et al. Glucocorticoid-induced 
leucine zipper is protective in Th1-mediated models of colitis. 
Gastroenterology. 2009;136(2):530–541.
 19. Cannarile L, Fallarino F, Agostini M, et al. Increased GILZ 
 expression in transgenic mice up-regulates Th-2 lymphokines. Blood. 
2006;107(3):1039–1047.
 20. Di Marco B, Massetti M, Bruscoli S, et al. Glucocorticoid-induced 
leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-
dimerization and C-terminal domain. Nucleic Acids Res. 2007;35(2): 
517–528.
 21. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper 
(GILZ): a new important mediator of glucocorticoid action. FASEB J. 
2009;23(11):3649–3658.
 22. Riccardi C. GILZ (glucocorticoid-induced leucine zipper), a media-
tor of the anti-inflammatory and immunosuppressive activity of 
glucocorticoids. Ann Ig. 2010;22(1 Suppl 1):53–59.
 23. Ayroldi E, Migliorati G, Bruscoli S, et al. Modulation of T-cell 
activation by the glucocorticoid-induced leucine zipper factor via 
 inhibition of nuclear factor kappaB. Blood. 2001;98(3):743–753.
 24. Ball LJ, Kuhne R, Schneider-Mergener J, Oschkinat H. Recognition 
of proline-rich motifs by protein-protein-interaction domains. Angew 
Chem Int Ed Engl. 2005;44(19):2852–2869.
 25. Ravi Chandra B, Gowthaman R, Raj Akhouri R, Gupta D, Sharma A. 
Distribution of proline-rich (PxxP) motifs in distinct proteomes: 
 functional and therapeutic implications for malaria and tuberculosis. 
Protein Eng Des Sel. 2004;17(2):175–182.
 26. Srinivasan M, Dunker AK. Proline rich motifs as drug targets in immune 
mediated disorders. Int J Pept. 2012;2012:634769.
 27. Srinivasan M, Janardhanam S. Novel p65 binding glucocorticoid-
induced leucine zipper peptide suppresses experimental autoimmune 
encephalomyelitis. J Biol Chem. 2011;286(52):44799–44810.
 28. Srinivasan M, Wardrop RM, Gienapp IE, Stuckman SS, Whitacre CC, 
Kaumaya PT. A retro-inverso peptide mimic of CD28 encompassing 
the MYPPPY motif adopts a polyproline type II helix and inhibits 
encephalitogenic T cells in vitro. J Immunol. 2001;167(1):578–585.
 29. Wang MH, Frishman LJ, Otteson DC. Intracellular delivery of proteins 
into mouse Muller glia cells in vitro and in vivo using Pep-1 transfection 
reagent. J Neurosci Methods. 2009;177(2):403–419.
 30. Klegeris A, Walker DG, McGeer PL. Regulation of glutamate in 
 cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. 
J Neuroimmunol. 1997;78(1–2):152–161.
 31. Lee M, Suk K, Kang Y, McGeer E, McGeer PL. Neurotoxic factors 
released by stimulated human monocytes and THP-1 cells. Brain Res. 
2011;1400:99–111.
 32. Harrison LM, Cherla RP, van den Hoogen C, et al. Comparative 
 evaluation of apoptosis induced by Shiga toxin 1 and/or lipopolysaccha-
rides in human monocytic and macrophage-like cells. Microb Pathog. 
2005;38(2–3):63–76.
 33. Sharif O, Bolshakov VN, Raines S, Newham P, Perkins ND. 
Transcriptional profiling of the LPS induced NF-kappaB response in 
macrophages. BMC Immunol. 2007;8:1.
 34. Mertlikova-Kaiserova H, Votruba I, Matousova M, Holy A, Hajek M. 
Role of caspases and CD95/Fas in the apoptotic effects of a nucleotide 
analog PMEG in CCRF-CEM cells. Anticancer Res. 2010;30(7): 
2791–2798.
 35. Cen O, Gorska MM, Stafford SJ, Sur S, Alam R. Identification of 
UNC119 as a novel activator of SRC-type tyrosine kinases. J Biol 
Chem. 2003;278(10):8837–8845.
 36. Srinivasan M, Gienapp IE, Stuckman SS, et al. Suppression of 
experimental autoimmune encephalomyelitis using peptide mimics of 
CD28. J Immunol. 2002;169(4):2180–2188.
 37. Klegeris A, Walker DG, McGeer PL. Toxicity of human THP-1 monocytic 
cells towards neuron-like cells is reduced by  non-steroidal anti-inflamma-
tory drugs (NSAIDs). Neuropharmacology. 1999;38(7): 1017–1025.
 38. Srinivasan M, Janardhanam S. Novel p65 binding glucocorti-
coid-induced leucine zipper peptide suppresses experimental 
autoimmune encephalomyelitis. J Biol Chem. 2011;286(52): 
44799–44810.
 39. Srinivasan R, Rose GD. A physical basis for protein secondary structure. 
Proc Natl Acad Sci U S A. 1999;96(25):14258–14263.
 40. Cubellis MV, Caillez F, Blundell TL, Lovell SC. Properties of 
polyproline II, a secondary structure element implicated in protein-
protein interactions. Proteins. 2005;58(4):880–892.
 41. Freund C, Schmalz HG, Sticht J, Kühne R. Proline-rich sequence recog-
nition domain (PRD): ligands, function and inhibition. In: Klussmann E, 
Scott J, editors. Protein-Protein Interactions as New Drug Targets. 
Heidelberg, Berlin, Germany: Springer-Verlag; 2008.
 42. Gu W, Helms V. Dynamical binding of proline-rich peptides to 
their recognition domains. Biochim Biophys Acta. 2005;1754(1–2): 
232–238.
 43. Zarrinpar A, Bhattacharyya RP, Lim WA. The structure and function 
of proline recognition domains. Sci STKE. 2003;2003(179):RE8.
Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2421
Glucocorticoid-induced leucine zipper and neuroinflammation
 44. Eguchi M, Kahn M. Design, synthesis, and application of pep-
tide secondary structure mimetics. Mini Rev Med Chem. 2002; 
2(5):447–462.
 45. Srinivasan M, Roeske RW. Immunomodulatory peptides from IgSF 
proteins: a review. Curr Protein Pept Sci. 2005;6(2):185–196.
 46. Cochran AG. Antagonists of protein-protein interactions. Chem Biol. 
2000;7(4):R85–R94.
 47. Unal EB, Gursoy A, Erman B. Conformational energies and entropies 
of peptides, and the peptide-protein binding problem. Phys Biol. 
2009;6(3):036014.
 48. Groner B, editor. Peptides as Drugs: Discovery and Development. 
 Weinheim, Germany: Wiley-VCH Verlag GmbH & Co KGaA; 2009.
 49. Guan QH, Pei DS, Zong YY, Xu TL, Zhang GY. Neuroprotection against 
ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal 
kinase (JNK) via nuclear and non-nuclear pathways. Neuroscience. 
2006;139(2):609–627.
 50. Mason JM. Design and development of peptides and peptide 
mimetics as antagonists for therapeutic intervention. Future Med Chem. 
2010;2(12):1813–1822.
 51. Kurzawa L, Pellerano M, Morris MC. PEP and CADY-mediated delivery 
of fluorescent peptides and proteins into living cells. Biochim Biophys 
Acta. 2010;1798(12):2274–2285.
 52. Bailey JA, Lahiri DK. A novel effect of rivastigmine on pre-synaptic 
proteins and neuronal viability in a neurodegeneration model of fetal 
rat primary cortical cultures and its implication in Alzheimer’s disease. 
J Neurochem. 2010;112(4):843–853.
 53. Bisht S, Khan MA, Bekhit M, et al. A polymeric nanoparticle 
formulation of curcumin (NanoCurc) ameliorates CCl4-induced 
hepatic injury and fibrosis through reduction of pro-inflammatory 
cytokines and stellate cell activation. Lab Invest. 2011;91(9): 
1383–1395.
 54. Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK. Neuroprotective and 
neurorescue effects of a novel polymeric nanoparticle formulation 
of curcumin (NanoCurc™) in the neuronal cell culture and animal 
model: implications for Alzheimer’s disease. J Alzheimers Dis. 
2011;23(1):61–77. 
 55. Zhang YH, Mann D, Raymick J, Sarkar S, Paule MG, Lahiri DK, 
Dumas M, Bell-Cohen A, Schmued LC. K114 inhibits A-beta aggre-
gation and inflammation in vitro and in vivo in AD/Tg mice. Curr 
Alzheimer Res. 2014;11(3):299–308.
 56. Hinkerohe D, Smikalla D, Schoebel A, et al. Dexamethasone pre-
vents LPS-induced microglial activation and astroglial impairment 
in an experimental bacterial meningitis co-culture model. Brain Res. 
2010;1329:45–54.
 57. Figuera-Losada M, Rojas C, Slusher BS. Inhibition of microglia 
 activation as a phenotypic assay in early drug discovery. J Biomol 
Screen. 2014;19(1):17–31.
 58. Srinivasan M, Lu D, Eri R, et al. CD80 binding polyproline heli-
cal peptide inhibits T cell activation. J Biol Chem. 2005;280(11): 
10149–10155.
 59. Srinivasan M, Srihari J. Glucocorticoid induced leucine zipper mimic 
inhibits experimental autoimmune encephalomyelitis. J Immunol. 
2012;188 (Meeting Abstract Supplement):Abstract 119.7.
 60. Ray B, Lahiri DK. Neuroinflammation in Alzheimer’s disease: different 
molecular targets and potential therapeutic agents including curcumin. 
Curr Opin Pharmacol. 2009;9(4):434–444.
